Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIDE study: antibody response after COVID-19 vaccination in people with Down syndrome
NL-OMON54387Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by University Medical Center Utrecht. Primary endpoints: SARS-CoV-2 spike-specific serum antibody concentration after second vaccination, Responder rate after second vaccination and 1 more. Started Feb 2021; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON54387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54387.